ReviewNature reviews. Urology2020
The microbiome and gynaecological cancer development, prevention and therapy.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 276 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
276 citing papers in PubMed, 5 syntheses or guidelines pooled it, 447 citations in OpenAlex.
- Microbiota composition of the female reproductive tract and miscarriage: a systematic review and meta-analysis.NPJ biofilms and microbiomes · 2026Pooled it
- Associations of the gut, cervical, and vaginal microbiota with cervical cancer: a systematic review and meta-analysis.BMC women's health · 2025Pooled it
- Multi-cohort ensemble learning framework for vaginal microbiome-based endometrial cancer detection.Frontiers in cellular and infection microbiology · 2025Pooled it
- Intratumoral microbiota composition in women's cancers: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- The Vaginal Microbiota, Human Papillomavirus Infection, and Cervical Carcinogenesis: A Systematic Review in the Latina Population.Journal of epidemiology and global health · 2024Pooled it
- Comprehensive nursing care for advanced digestive malignancy patients during chemotherapy based on probiotic intervention: a randomized controlled study on improvement of gastrointestinal function and prevention of complications.Frontiers in cellular and infection microbiology · 2025Trial
- Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).Gynecologic oncology · 2023Trial
- Effect of Lactobacillus delbrueckii subsp. lactis on vaginal radiotherapy for gynecological cancer.Scientific reports · 2023Trial
- The cervicovaginal microbiome: an emerging determinant of HPV infection and disease.Journal of virology · 2026Review
- Review
- Transkingdom interactions between HPV and the microbiome in the female reproductive tract: Gaps, challenges, and emerging perspectives.PLoS pathogens · 2026Article
- The Influence of Vaginal, Intestinal, and Tumor Tissue Microbiota on Selected Malignant Tumors in Women.International journal of molecular sciences · 2026Review
- Assessing the female urogenital-rectal axis microbiome: focus on endometriosis and recurrent implantation failure.Reproductive biology and endocrinology : RB&E · 2026Article
- Article
- Genomic landscape of the human vaginal microbiome is linked to host genetics and population of origin.Nature genetics · 2026Article
- Bidirectional Interactions Between Cervicovaginal Microbiota and Human Papillomavirus Drive Persistence and Disease Progression.International journal of molecular sciences · 2026Review
- Preoperative Vaginal Microbiota and Risk of Complications After Transobturator Tape Surgery: A Pilot Study.Journal of clinical medicine · 2026Article
- Integrated culturomics and 16S rDNA sequencing reveal a functional microbiome signature in endometrial cancer.BMC microbiology · 2026Article
- Gut-reproduction axis: genome-wide pleiotropic and prospective evidence linking inflammatory bowel disease with gynecological disorders.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Understanding The Role of Lacticaseibacillus rhamnosus in Vaginal Dysbiosis: in Vitro Studies and Clinical Evidence.Probiotics and antimicrobial proteins · 2026Review
216 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The female reproductive tract (FRT), similar to other mucosal sites, harbours a site-specific microbiome, which has an essential role in maintaining health and homeostasis. In the majority of women of reproductive age, the microbiota of the lower FRT (vagina and cervix) microenvironment is dominated by Lactobacillus species, which benefit the host through symbiotic relationships. By contrast, the upper FRT (uterus, Fallopian tubes and ovaries) might be sterile in healthy individuals or contain a low-biomass microbiome with a diverse mixture of microorganisms. When dysbiosis occurs, altered immune and metabolic signalling can affect hallmarks of cancer, including chronic inflammation, epithelial barrier breach, changes in cellular proliferation and apoptosis, genome instability, angiogenesis and metabolic dysregulation. These pathophysiological changes might lead to gynaecological cancer. Emerging evidence shows that genital dysbiosis and/or specific bacteria might have an active role in the development and/or progression and metastasis of gynaecological malignancies, such as cervical, endometrial and ovarian cancers, through direct and indirect mechanisms, including modulation of oestrogen metabolism. Cancer therapies might also alter microbiota at sites throughout the body. Reciprocally, microbiota composition can influence the efficacy and toxic effects of cancer therapies, as well as quality of life following cancer treatment. Modulation of the microbiome via probiotics or microbiota transplant might prove useful in improving responsiveness to cancer treatment and quality of life. Elucidating these complex host-microbiome interactions, including the crosstalk between distal and local sites, will translate into interventions for prevention, therapeutic efficacy and toxic effects to enhance health outcomes for women with gynaecological cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.